Jan 17 (Reuters) - Vernon Hugh Bowman is the rare Indiana
soybean farmer destined for immortality as a U.S. Supreme Court
caption.
Bowman had the temerity to attempt to outwit Monsanto, the
giant agriculture company that, as you surely know, invested
hundreds of millions of dollars and years of research in the
creation of soybean seeds that are genetically modified to
withstand the herbicide glyphosate, which Monsanto markets as
Roundup. The genetically modified seeds, according to the
Supreme Court brief Monsanto filed Wednesday, have been such a
hit with farmers that more than 90 percent of the U.S. soybean
crop begins with Monsanto's Roundup Ready seeds. Given that
every soybean plant produces enough seeds to grow 80 more plants
-- and that soybeans grown from Roundup Ready seeds contain the
genetic modification of glyphosate resistance -- Monsanto has
insisted that farmers sign licensing agreements with strict
restrictions. Soybean producers are only supposed to use the
Roundup Ready seeds they buy to grow crops in a single season,
and they're forbidden from planting second-generation seeds
harvested from first-generation crops.
The licensing agreements do contain an exception, though:
Farmers are allowed to sell the second-generation seeds to grain
elevators, which, in turn, are permitted to sell a mixture of
undifferentiated seeds as "commodity grain." Monsanto contends
that commodity grain should be used for feed, not cultivation.
But Bowman figured that the mixture sold by grain elevators
probably contained mostly Roundup Ready seeds, so for several
years, after harvesting his first crop (planted with authorized,
Monsanto-licensed seeds), he planted a second crop with
commodity grain. When he treated the second crop with herbicide,
he was proved right -- most of the plants were resistant.
Monsanto took grave exception to Bowman's ingenuity and sued
him for infringing its Roundup Ready patents by using, without
authorization, seeds that embodied its technology. The farmer
argued that under the doctrine of patent exhaustion, as
interpreted most recently by the Supreme Court in the 2008 case
of Quanta Computer v. LG Electronics, Monsanto only had the
right to control use of the first-generation seeds. Using
second-generation seeds, the farmer said, was akin to reselling
a patented product you'd already paid for. U.S. District Judge
Richard Young of Indiana disagreed. He granted summary judgment
to Monsanto and awarded the company about $85,000 in damages.
Bowman revived his patent exhaustion argument at the Federal
Circuit Court of Appeals, which has already twice upheld
Monsanto's right to bar farmers from planting second-generation
seeds they've harvested from their own first-generation Roundup
Ready crops. Not surprisingly, the appeals court sided with
Monsanto and said the company's patent rights were not exhausted
in the first-generation harvest. But the Federal Circuit's
September 2011 decision was notable for an additional
affirmation of Monsanto's rights. Even if patent exhaustion did
apply, the appeals court held, Bowman infringed anew when he
grew a crop that embodied Monsanto's patented technology. Any
other interpretation, the court said, would eviscerate
Monsanto's rights as a patent holder.
The Supreme Court had declined to review those two previous
Federal Circuit decisions approving Monsanto's restriction on
the use of Roundup Ready seeds, but the justices granted
Bowman's cert petition in October 2012. His lawyers at Frommer
Lawrence & Haug filed their merits brief in December, and
Monsanto filed its reply on Wednesday.
The farmer and the corporate giant can't even agree on
precisely what question the case presents. Bowman asserted that
the issue is the Federal Circuit's refusal to abide by Supreme
Court precedent, which, according to the farmer, dictates that
patent rights are exhausted after the authorized sale of a
patented product. (It's always a good strategy to tell the
Supreme Court that the Federal Circuit is disobeying its
directives on the scope of patents.) Bowman's brief went even
further and accused the Federal Circuit of usurping Congress and
making new law that carves out "an exception to the doctrine of
patent exhaustion for self-replicating technologies.
Monsanto, which is represented by Supreme Court veteran Seth
Waxman of Wilmer Cutler Pickering Hale and Dorr, said in
Wednesday's brief that the issue is a patent holder's right to
impose restrictions on the use of its technology, which extends
to unauthorized copies of patented products. Monsanto's brief
warns that if the justices adopt Bowman's position -- that (as
Monsanto articulates it) "patent law treats as per se
unenforceable all restrictions imposed by license on the use of
a patented article following an authorized sale" -- the biotech
industry will be devastated.
Monsanto is a vigorous enforcer of its patent rights, so
Bowman has attracted considerable amicus support from public
interest groups. The U.S. government, on the other hand, sided
with Monsanto in the amicus brief it filed last week, arguing
that Bowman was misinterpreting the doctrine of patent
exhaustion. "Under longstanding principles of patent exhaustion,
an initial authorized sale of an article embodying the patented
invention exhausts the patentee's exclusive rights to control
the use and sale of that article," the Justice Department said.
"It does not, however, exhaust the patentee's right to exclude
others from making a new article embodying the same patented
invention. Accordingly, even if respondent's patent rights in
the commodity seed had been exhausted, petitioner acquired no
right to use that seed to make newly infringing seed."
Though it has received considerably less attention than the
Myriad gene patent case, which the Supreme Court is also hearing
this term, Bowman v. Monsanto implicates similar big-picture
concerns about the scope of patent rights and the impact of
those rights on critical research. Whatever you think about
genetically modified food, this is a case to watch.
(Reporting by Alison Frankel)
Follow us on Twitter: @AlisonFrankel, @ReutersLegal | Like us on Facebook